← All trials
NCT05541250
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2022
- Primary completion
- Sep 29, 2026
- Completion date
- Sep 29, 2026
- First posted
- Sep 15, 2022
- Last posted
- Nov 15, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MiamiLead sponsor
- University of MiamiSponsor investigator
- University of MiamiStudy chair
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.